Testosterone undecanoate: a useful tool for testosterone administration in rats

Exp Clin Endocrinol Diabetes. 2003 Jun;111(4):203-8. doi: 10.1055/s-2003-40464.

Abstract

A major obstacle of testosterone (T) treatment in experimental animals is the difficulty of maintaining long-term physiologic/anabolic steady serum levels after exogenous T administration. In two complementary studies we investigated the pharmacokinetic properties of different T formulations in male rats. Study I. Mature male Wistar rats (> 380 g, n = 4 - 7/group) were divided into four treatment groups: (1) sham-operated non orchiectomised (non-ORX) and placebo; (2) orchiectomised (ORX) and subcutaneous testosterone pellets (TP) (15, 25, 75 mg/60 days release or placebo pellets); (3) ORX and a single injection of testosterone undecanoate (TUD) (31, 62.5 or 125 mg/kg body weight subcutaneously (s.c.) or vehicle; (4) ORX and testosterone propionate (Tprop) (10, 20, 40 mg/month) or vehicle as a single injection s.c. Serum T was measured at baseline and in weekly intervals for 4 weeks. Study II. Mature male Wistar rats (180 - 200 g) were randomly assigned to one of 5 experimental groups (n = 5 - 6/group): (1) normal untreated rats (controls); (2) ORX untreated rats, and non-ORX rats receiving one of three treatment options; (3) 250 mg/kg body weight TUD i.m. (TUD 250); (4) 500 mg/kg body weight TUD i.m. (TUD 500); (5) 100-mg testosterone pellet/90 days release s.c. (TP 100). Serum T was measured at baseline and in intervals for 6 weeks after T administration. In both studies, the kinetic profile of TUD showed favourable continuous steady state levels over several weeks. In contrast, testosterone release by subcutaneous pellets resulted in a shorter than expected duration of elevated serum T levels with high inter-individual variability. Tprop administration led to only a short-lasting serum T increase with low serum T levels already 14 days after injection. In conclusion, a single injection of TUD (100 mg/kg body weight s.c.) is effective in inducing physiological testosterone levels in ORX rats for a minimum of four weeks. High dose TUD (500 mg/kg body weight i.m.) given as a single injection results in supraphysiological anabolic testosterone concentrations for up to six weeks in non-ORX rats. TUD was superior to other T release preparations and represents a convenient and effective tool for T administration in experimental animals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anabolic Agents / administration & dosage*
  • Anabolic Agents / pharmacokinetics*
  • Animals
  • Dose-Response Relationship, Drug
  • Drug Implants
  • Injections, Intramuscular
  • Injections, Subcutaneous
  • Male
  • Orchiectomy
  • Rats
  • Rats, Wistar
  • Testosterone / administration & dosage*
  • Testosterone / analogs & derivatives*
  • Testosterone / pharmacokinetics*
  • Testosterone Propionate / administration & dosage
  • Testosterone Propionate / pharmacokinetics

Substances

  • Anabolic Agents
  • Drug Implants
  • Testosterone
  • testosterone undecanoate
  • Testosterone Propionate